



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



**VU0661013**  
Item No. 39524

**CAS Registry No.:** 2131184-57-9  
**Formal Name:** 3-[(4R)-7-chloro-10-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-3,4-dihydro-4-methyl-1-oxo-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrazino[1,2-a]indol-2(1H)-yl]-1-methyl-1H-indole-5-carboxylic acid  
**MF:** C<sub>39</sub>H<sub>39</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>4</sub>  
**FW:** 712.7  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

VU0661013 is supplied as a solid. A stock solution may be made by dissolving the VU0661013 in the solvent of choice, which should be purged with an inert gas. VU0661013 is soluble in DMSO and methanol.

## Description

VU0661013 is an inhibitor of myeloid cell leukemia-1 (Mcl-1; K<sub>i</sub> = 97 pM).<sup>1</sup> It is selective for Mcl-1 over Bcl-xL and Bcl-2 (K<sub>i</sub>s = >40 and 0.73 μM, respectively). VU0661013 inhibits cell growth in a panel of acute myeloid leukemia (AML) cell lines (GI<sub>50</sub>s = 0.16-7.62 μM). It decreases blood, bone marrow, and spleen leukemic burden, reduces splenomegaly, and increases survival in a MV4-11 disseminated AML mouse xenograft model when administered at a dose of 75 mg/kg. VU0661013 also selectively inhibits glutathione peroxidase 4 (GPX4; IC<sub>50</sub> = 8.4 μM) over GPX1, GPX2, glutathione reductase (GR), and thioredoxin reductase 1 (TrxR1).<sup>2</sup>

## References

1. Ramsey, H.E., Fischer, M.A., Lee, T., *et al.* A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. *Cancer Discov.* **8(12)**, 1566-1581 (2018).
2. Cheff, D.M., Cheng, Q., Guo, H., *et al.* Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4. *Redox Biol.* **63:102719**, (2023).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2023

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM